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The Netherlands
ABSTRACT
Introduction: Several techniques can be used to treat intravesical chemohyperthermia (ChHT). We
compared radiofrequency-induced hyperthermia (RF-HT) with conductive hyperthermia (C-HT) for their
ability to induce bladder wall temperatures of >40.5 C, the target temperature for ChHT.
Materials and Methods: Fresh porcine bladders (n¼ 12) were placed in a temperature-controlled
saline bath to simulate body temperature and circulation. HT was induced with RF-HT (43 C) or C-HT
(inflow temperature 44 and 46 C) using a custom-made device. In two additional bladders, we varied
intravesical solution and volume. Temperatures were recorded with a three-way catheter containing
three mucosal and two urethral thermocouples (TCs) and a 915MHz RF antenna, and with external
TCs in the bladder wall at three different levels and three different locations.
Results: Target temperature (40.5 C) was reached in the submucosa at all locations by both techni-
ques. In the detrusor, target temperature was reached by RF-HT at the bladder neck and side wall. C-
HT46 reached significantly higher submucosal temperatures at the side wall. The bladder dome
seemed best heated by C-HT, although a high inflow temperature (46 vs. 44 C) was required (ns).
Intravesical saline resulted in higher temperatures than sterile water for RF-HT. A volume of 100mL
resulted in higher bladder dome temperatures for RF-HT, and higher bladder neck with lower dome
temperatures for C-HT.
Conclusion: Our results indicate a slightly superior heating capacity for RF-HT compared to C-HT,
whereas for the bladder dome, the reverse seems true. Comparative studies are warranted to evaluate
whether HT efficacy differs between both techniques, with emphasis on tumor location.
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Introduction
Bladder cancer is a commonly occurring disease, predominantly
found in Caucasian men [1–3]. At first diagnosis, about 75% of
patients present with non-muscle invasive bladder cancer
(NMIBC). It has a recurrence rate of up to 52% after 5years, and
a chance of progression to muscle invasive disease (MIBC) of up
to 20% [4]. Current treatment guidelines advise a transurethral
resection of the bladder tumor, followed by adjuvant intravesical
chemotherapy, typically using cold instillations of Mitomycin C
(MMC), or immunotherapy with Bacille Calmette-Guerin (BCG).
The exact type and scheme of adjuvant instillations depends on
the patient’s risk category for recurrence and progression [5].
A currently available alternative treatment option for
NMIBC is intravesical chemohyperthermia (ChHT). A promis-
ing and effective technique appears to be radiofrequency
(RF)-induced ChHT (RF-ChHT), in which typically MMC is used
[6,7]. It compares favorably to standard MMC instillations,
with 59% less recurrences after RF-ChHT when compared to
cold MMC alone [6], and to BCG immunotherapy, with 2-year
recurrence free survival (RFS) rates in intermediate-high risk
NMIBC patients of 82% vs. 65%, respectively (p¼ .02) [8].
In another technique for intravesical ChHT known as con-
ductive ChHT (C-ChHT), the drug solution is heated extracor-
poreally before intravesical recirculation. Although this
technique seems less complex than RF-ChHT, current evi-
dence for its efficacy is limited. Only five explorative studies
using two different devices have been published, showing a
2-year RFS rate in intermediate-high risk NMIBC patients of
up to 88% in the adjuvant setting [9–13]. No comparison has
been made with MMC or BCG therapy.
For any kind of intravesical ChHT to be effective a critical
temperature of 40.5 C or higher must be reached at the
mucosa, submucosa and, for potential use in MIBC, detrusor
level of the bladder wall [14,15]. In the absence of compara-
tive clinical studies, we aimed to compare the capacity to
heat the bladder wall at several depths using RF-induced
hyperthermia (RF-HT) vs. conductive hyperthermia (C-HT) in a
pig post-mortem bladder model.
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Materials and methods
The post-mortem bladder model
Bladders were taken from 12 female pigs weighing
80–100 kg from a commercial slaughterhouse within 3 h of
sacrifice. They were placed in a temperature-controlled 0.9%
NaCl bath to simulate body temperature and heat dissipation
(flow organ bath 2.0 L/min, volume 10 L). The temperature of
the organ bath was kept constant at 37 C to mimic that of
humans. A three-way 20-French catheter containing three
mucosal and two urethral thermocouples (TCs) and a
915MHz RF antenna was placed intravesically. Additional TCs
were surgically placed at different tissue levels (Figure 1). A
solution of 50mL of NaCl 0.9% was used intravesically.
Subsequently, hyperthermia (HT) of 43 C at luminal
mucosa level was induced using either RF-HT or C-HT. We
used a custom-made, non-commercially available system
consisting of a heat-exchanger (Medtronic MYOtherm XPVR ,
Minneapolis, MN, USA) and a centrifugal pump (Medtronic
BP-50 Bio-PumpVR ) to fine-tune inflow temperature and flow.
We continuously and actively measured the flow (mL/min)
and fluid temperature at three levels: catheter connector,
urethra and luminal mucosa. The latter was fine-tuned to
keep temperature stable at 43 C. Flow was measured using
the EmTec Sono TTTM (New York, NY, USA) ultrasonic
FlowComputer. For C-HT, a flow of 180 ± 20mL/min and an
inflow temperature of 46 ± 0.8 C was used (C-HT46).
Additionally, we studied an inflow temperature of 44 C for
C-HT (C-HT44) to evaluate the effect of a lower inflow tem-
perature as in clinical use, 46 C may cause potential urethral
burning or pain. The SynergoVR device (Medical Enterprises
Ltd., Amsterdam, The Netherlands) [7] was used for RF-HT
with a flow of 5–10mL/min and an inflow temperature of
31 ± 2 C. Here again, the flow and inflow temperature were
fine-tuned using the custom-made circulation system.
In addition to studying the different HT techniques, we eval-
uated the effect of different intravesical solutions (sterile water
vs. saline) and intravesical volumes (50mL vs. 100mL) in two
additional bladders to study effects on heating capacity of a
volume increase due to urine production (Figure 2).
We varied the experimental order to prevent any influ-
ence on the temperature measurements resulting from the
sequence of experiments within the ex-vivo bladders.
Comparative experiments were performed within the same
bladders, thus minimizing inter-individual differences that
might obscure differences between the techniques tested. By
doing so, each bladder functioned as its own control. No
approval of any ethical committee was required.
Temperature mapping
A schematic illustration of the experimental set-up is given
in Figure 1.
Luminal and urethral temperatures were monitored using
the SynergoVR system and facilitated temperature stabilisa-
tion. Additional external T-type (constantan-cupper) TCs with
a 0.6 ± 0.1mm tip length were surgically placed in the blad-
der wall at three different locations, the bladder neck
(TC1–TC3), side wall (TC4–TC6), and bladder dome (TC7–TC9),
resulting in a total of nine TCs located in the bladder wall.
At each location, the TCs were placed at different levels in
ascending order (submucosa, mid-detrusor and serosa) and
Legenda
Thermocouple (TC)
Locaon of triplet TC-set
Radiofrequency source
Centrifugal pump 
Heat exchanger
Organ bath (T = 37°C)
43°C 
Lumen 
Mucosa & 
submucosa Detrusor Serosa
In- & oulow TCs Urethral TCs Luminal mucosa TCs
TCs1,4,7 (submucosa) 
TCs2,5,8 (detrusor) 
TCs3,6,9 (serosa)
Figure 1. Experimental set-up. The heat-exchanger was used for C-HT, the radiofrequency source for RF-HT. Temperatures were measured at several locations.
C-HT: conductive hyperthermia; RF-HT: radiofrequency induced hyperthermia; TC: thermocouple.
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fixed using tissue glue (Dermaþ FlexVR , Chemence Medical
Products, Inc., Alpharetta, GA, USA) and 6–0 polypropylene
sutures (Prolene, Ethicon, LLC., Somerville, NJ, USA). Organ
bath temperatures were monitored with two separate TCs
(TC10 and TC11). We additionally measured the inflow (TC12)
and outflow (TC13) temperatures at about 60 cm from the
catheter tip as this is similar to where the inflow temperature
is monitored in one of the currently available C-HT techni-
ques [9]. Although the extra-corporeal heating of fluid in our
study was performed by a custom-made system rather than
a commercially available system, the inflow temperature was
measured at a similar distance from the catheter tip. Bladder
wall, inflow, outflow and organ bath temperatures were
recorded every minute for 10min using a Keithley
Multiplexer device (CN Rood, Zoetermeer, The Netherlands)
containing an internal cold junction. The TCs were calibrated
using ice water as 0 C and had a ±0.1 C accuracy. Bladder
wall temperatures were averaged and compared between
the different techniques and circumstances.
Data analysis and statistics
Temperatures were compared by box plot and analysis of
variance (ANOVA) for comparison of the multiple means
recorded for the different techniques and locations.
Additionally, the values depicting the temperature above
which 90% and 50% of the observed temperatures were
observed (T90 and T50) and the cumulative equivalent
minutes of T90 above 43 C (CEM43T90) were calculated as a
measure for the thermal dose applied.
All analyses were performed using R statistical package
version 3.2.4 Revised (2016, The R Foundation for Statistical
Computing, Vienna, Austria).
A temperature of 40.5 C or higher was regarded an
effective hyperthermic temperature [14,15].
Results
Twelve different bladders were used for the heating efficacy
analysis. Thickness of the bladder wall varied from 3 to 8mm.
The mucosa as measured at the posterior bladder wall was
140–230 mm thick. The RF energy needed to heat the mucosa
to a temperature of 43 C varied between 14–37 W. The aver-
age luminal mucosa temperatures were 43.1 ± 0.22 C,
44.0 ± 0.92 C and 42.5 ± 0.73 C for RF-HT, C-HT46 and C-HT44,
respectively.
The temperature descriptives (T90, T50, CEM43T90 and
mean) per location and technique are presented in Table 1.
Mean bladder wall temperatures differed significantly
between the three groups (ANOVA p< .05 for all), although
this was mainly due to differences between RF-HT and the
C-HT44 group. Mean urethral temperatures were 37.4 ± 3.0 C,
45.4 ± 0.4 C and 43.5 ± 0.4 C for RF-HT, C-HT46 and C-HT44,
respectively. Environmental temperatures varied from 21.5
to 24.3 C.
All techniques (RF-HT, C-HT46 and C-HT44) reached the tar-
get temperature at the submucosa level. However, signifi-
cantly higher mean bladder wall temperatures were seen
after RF-HT compared to C-HT44 at the bladder neck and
side wall (Figure 3). At the bladder neck, this difference was
noted even when the inflow temperature for C-HT was
increased from 44 to 46 C, although the difference was only
significant at the detrusor level (p< .05). Importantly, RF-HT
reached the critical effective mild hyperthermic temperature
of 40.5 C in the detrusor, whereas C-HT did not (Figure 3),
reflecting a deeper heat penetration into the bladder wall for
RF-HT. At the bladder side wall, C-HT46 reached a signifi-
cantly higher mean temperature at the submucosa (p< .05),
although the target temperature was reached by both tech-
niques. At the detrusor level, RF-HT again reached a mean
temperature of 40.5 C, whereas C-HT did not; here the dif-
ference between the temperature measurements was not
significant (p¼ .54). C-HT reached higher temperatures at the
bladder dome compared to RF-HT, although the target tem-
perature was still reached by RF-HT (p¼ ns). The heating cap-
acity and its relation between RF-HT and C-HT is additionally
well depicted by the CEM43T90 values (Table 1), supporting
the relationships described above. In one pig bladder,
extremely high submucosal temperatures at the bladder
dome were measured during RF-HT (submucosal tempera-
ture of 52.39 C), explaining the outlier in Figure 3. This was
probably due to the close proximity of the TC to the RF-
antenna during RF-HT. In one other bladder, one with a thin-
ner bladder wall (4–5mm), a reverse pattern with C-HT out-
performing RF-HT at all locations was observed (data
not shown).
Because saline and sterile water are used for bladder irri-
gation in the clinic, we compared the effect of using both
these intravesical fluids. For both techniques saline resulted
in higher temperatures compared to sterile water at all loca-
tions, although this effect was less pronounced for C-HT
(Supplementary Figure 1).
Figure 2. Flow diagram of experimental groups. C-HT: conductive hyperthermia; H2O: sterile water; NaCl: sodium chloride (i.e., saline); RF-HT: radiofrequency
induced hyperthermia.
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Lastly, the installation volume was varied, as larger vol-
umes (and a more extended bladder) might alter the tem-
perature distribution. The use of either 50mL or 100mL
intravesical volume did not result in different bladder wall
temperatures at the bladder neck and side wall for RF-HT
(Supplementary Table 1). With a volume of 100mL, higher
temperatures were reached at the bladder dome, although
the critical temperature of 40.5 C was not reached. For C-HT,
a volume of 100mL was beneficial for bladder neck heating,
whereas 50mL resulted in higher temperatures of the side
wall and dome (Supplementary Figure 2). However, the dif-
ferences were small and too few bladders (n¼ 2) were tested
to draw reliable conclusions.
Discussion
The combination of intravesical chemotherapy and RF-HT
proved more effective in preventing recurrences of NMIBC
than the current standard therapies (MMC alone or BCG
immunotherapy) for intermediate to high risk NMIBC [7–13].
HT, however, can be induced by several techniques, and for
intravesical use, C-HT and RF-HT are available. We hypothe-
sized that a difference in heating capacity between these
two most commonly used techniques of inducing hyperther-
mia might exist, and we compared both methods in an ex-
vivo porcine bladder model for its ability to heat the bladder
wall to a minimum temperature of 40.5 C. Our results show
that using a custom-made device, slight differences in the
capacity to heat between RF-HT and C-HT exist, in which
bladder wall temperatures differ per region and per individ-
ual bladder. The minimum effective mild hyperthermic tem-
perature of 40.5 C was generally reached in the submucosa
at all locations using either technique. However, in the
detrusor, the target temperature was only reached at the
bladder neck using RF-HT (statistically different from C-HT),
and at the side wall by RF-HT (no statistical difference with
C-HT46). Thus, the bladder neck can best be heated by RF-
HT. This is supported by the calculated CEM43T90 values.
Table 1. Bladder wall temperatures per location and technique.
Measurement RF-HT C-HT (46 C) C-HT (44 C)
Location T90 T50 CEM43T90 mean T T90 T50 CEM43T90 mean T T90 T50 CEM43T90 mean T
Bladder neck Mucosa 40.40 42.35 0.27 41.95 40.26 41.83 0.22 41.70 39.65 40.69 0.10 40.59
Detrusor 39.67 41.62 0.10 41.43 39.05 40.74 0.04 40.33 38.50 39.81 0.02 39.58
Serosa 38.46 39.34 0.02 39.53 37.96 39.12 0.01 39.10 37.82 38.66 0.01 38.62
Bladder side wall Mucosa 39.91 41.91 0.14 41.49 40.53 42.26 0.33 42.02 39.66 40.94 0.10 40.87
Detrusor 39.33 40.29 0.06 40.61 39.55 40.13 0.08 40.36 39.09 39.41 0.04 39.63
Serosa 38.22 39.24 0.01 39.18 38.37 38.82 0.02 39.22 38.07 38.42 0.01 38.77
Bladder dome Mucosa 40.18 41.12 0.20 41.86 40.52 42.24 0.32 41.92 39.85 41.06 0.13 40.86
Detrusor 38.70 39.74 0.03 40.17 39.39 40.09 0.07 40.23 38.77 39.48 0.03 39.55
Serosa 37.99 38.58 0.01 38.83 38.02 38.95 0.01 39.07 37.79 38.62 0.01 38.65
All temperatures are in C. C-HT: conductive hyperthermia; CEM43T90: cumulative equivalent minutes of T90 above 43 C (heating occurred for
10min); Detr: detrusor; RF-HT: radiofrequency-induced hyperthermia; T: temperature; T50: temperature above which 50% of the measured val-
ues are observed; T90: temperature above which 90% of the measured values are observed; V: volume in mL.p< .05 compared to RF-HT.p< .01 compared to RF-HT.p< .001 compared to RF-HT.
RF-HT C-HT46 C-HT44
Bladder domeBladder neck Bladder side wall
SerosaSubmucosa Detrusor Submucosa DetrusorSubmucosa Detrusor Serosa Serosa
Target temperature
***
**
*
*
* ***
*
Figure 3. Boxplot of temperatures in the bladder wall after RF-HT, C-HT46, and C-HT44. Dashed horizontal line represents the target temperature of 40.5 C. Bold hori-
zontal bars represent the median value. C-HT44: conductive hyperthermia with an inflow temperature of 44 C; C-HT46: conductive hyperthermia with an inflow tem-
perature of 46 C; RF-HT: radiofrequency induced hyperthermia. p< .05 compared to RF-HT. p< .01 compared to RF-HT. p< .001 compared to RF-HT.
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The bladder dome, however, seems best heated by C-HT,
although a high inflow temperature of 46 C is needed and
the difference with RF-HT was not statistically different.
Given that only 14–18% of high grade NMIBC tumors are
located at the dome, the potential clinical relevance is
restricted to those tumors [16]. At the bladder side wall, the
bladder submucosa was significantly better heated by C-HT46
compared to RF-HT, but C-HT46 did not reach the minimum
effective hyperthermic temperature at the detrusor level,
whereas RF-HT did. The serosa is generally not heated to
effective temperatures and if so, after RF-HT at the bladder
neck only (data of a single separate bladder, data
not shown).
The differences in heating capacity per region of the blad-
der and per anatomical depth layer was unanticipated, and
is important in view of the current clinical use. It should be
stressed that treatment of the dome is a challenge in any
intravesical therapy, especially ChHT, as both the drug and
heat need to be sufficiently transferred to the dome. In our
study, RF-HT seemed to penetrate deeper into the different
anatomical layers of the bladder wall. With RF-HT, an effect-
ive mild hyperthermic temperature in the detrusor layer of
the bladder neck and side wall could be more easily reached
in most of the bladders, compared with C-HT with an inflow
temperature of 46 C. Achieving effective hyperthermic tem-
peratures at these depths may be beneficial for NMIBC
patients if any residual tumor after TURBT is present (imply-
ing incomplete TURBT). Additionally, an increased amount of
collagen in papillary tumor or sub-epithelial stroma is associ-
ated with progression to muscle invasion, which might be
better heated by RF-HT [17]. In treatment of minimally
muscle-invasive disease, HT at the detrusor level might be of
value in experimental bladder-sparing therapy, for example
with thermosensitive nanoparticles [18,19]. Thus, whereas a
tumor located at the bladder neck or side wall seems to be
well-heated by RF-HT, using C-HT for tumors growing at the
bladder dome could be considered, as C-HT seemed to
achieve higher temperatures there.
Remarkably, in one of the bladders investigated, C-HT was
clearly more effective than RF-HT in bladder heating in con-
trast to the other bladders. This emphasizes inter-individual
variation. The wall of this bladder was one of the thinner
(maximum 5mm) bladders studied, possibly explaining this
difference. This might imply consequences for women in par-
ticular, given that their bladder wall is generally thinner com-
pared to men due to a lower urethral resistance.
Alternatively, methodological variation might influence the
heating capacity (e.g., catheter positioning) or temperature
measurement (e.g., TC positioning). The variation in heating
capacity of the two techniques in combination with target
temperatures reached in different bladder regions within a
single bladder may partially explain variation in the individ-
ual response to chemohyperthermic treatment in the clinic,
and thus result in a preference for C-HT in women.
Temperatures of 40.5 C or higher are required to achieve
a chemohyperthermic treatment effect [14,15]. However, effi-
cacy increases when higher temperatures are reached
[20,21]. In this sense, it is important to note that in most
bladders, the highest temperatures were reached using RF-
HT, or with our custom-made C-HT device at a 46 C inflow
temperature. C-HT with a 44 C inflow temperature generally
resulted in the lowest (ineffective) bladder wall temperatures.
This would indicate that either RF-HT or C-HT with a 46 C
inflow temperature be the best options in clinical use.
However, a 46 C inflow temperature resulted in high ureth-
ral temperatures ranging from 44.5 to 46.1 C, temperatures
that are known to produce local adverse events such as
pain, bladder spasms and discomfort. This could be solved
by designing a dedicated catheter which allows an inlet tem-
perature of 46 C while assuring that the urethra temperature
remains bearable. Thus, a specific catheter which is either
well insulated or able to simultaneously cool the urethra is
needed to be able to apply these temperatures in patients. A
recent conference abstract on a clinically approved device
for C-HT has evaluated these potential side-effects in inter-
mediate risk NMIBC patients (n¼ 307) and found no signifi-
cant differences between C-HT and normothermic MMC on
pain, dysuria, urgency, incontinence, nocturia, urinary tract
infection, allergic reactions or urethral strictures [22]. Urinary
frequency, hematuria, and bladder spasm were significantly
more frequently observed after C-HT. Worthy of note is that
an inflow temperature of 43 C was used, and no data on
efficacy have yet been reported.
Intravesical instillation of saline resulted in higher bladder
wall temperatures than sterile water; this was most pro-
nounced for RF-HT. The higher heat conductivity to the tis-
sue may be due to the higher number of ions in the saline
solution. Specifically, RF waves are known to be partially
reflected and absorbed by ion-rich fluids [23–25].
Consequently, RF waves are spread throughout the bladder
more evenly, possibly leading to more homogeneous heating
compared to sterile water. Additionally, an intravesical vol-
ume of 100mL resulted in higher bladder dome tempera-
tures for RF-HT, whereas 100mL resulted in higher bladder
neck and lower dome temperatures for C-HT. This possibly
reflects the different anatomy of the more extended bladder,
leading to improved contact with the surface area. Both the
results on the intravesical fluid and the volume used for
instillation indicate that these factors might influence ChHT
efficacy and thus could be adapted to the individual patient
if only one technique is available. Moreover, it suggests that
a limited amount of urine production during a treatment ses-
sion does not hamper the heating capacity, although any
chemotherapeutic intravesical drug will be diluted by urine
production. It needs to be stated that intravesical volume
and solution were only studied in two bladders, and there-
fore these results should be viewed with caution.
In two other studies, the bladder tissue temperatures
associated with the heating techniques used in this study
were examined [26,27]. In a recent conference abstract, the
results of the Combat BRS device for C-HT in pigs were
described. In this in-vivo study, C-HT was able to heat the
bladder lumen to a temperature of 42.9 ± 0.14 C and gener-
ated a transmural gradient of 1.5 C across the detrusor,
resulting in full thickness bladder heating of >41 C [27].
However, no comparison with RF-HT was made, and no
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information on the inflow temperature of the C-HT was
given. In the other in-vivo study, two sheep were treated
with RF-ChHT to study the safety of the hyperthermia treat-
ment [26]. Temperatures at the luminal mucosa, the external
bladder level, and the surrounding organs were measured.
The authors concluded that RF-HT combined with intravesi-
cal chemotherapy was a safe therapeutic option with no irre-
versible thermal damage to the bladder or adjacent tissues.
Similar to our experiments, the variation of temperatures per
bladder region and per animal was observed. The median
luminal mucosa temperature was 44.7 C (range 39.9–46.3 C)
and the median extravesical temperature was 39.5 C (range
37.2–42.6 C) in the two sheep. Temperatures inside the blad-
der wall were not evaluated. The heating phase at the begin-
ning of the treatment session to reach effective mucosal
temperatures took about 10min. We only evaluated the
equilibrium phase in our study. As our model was ex-vivo
and vascularization is an important factor in the heating
phase, we found it of insufficient value to evaluate the heat-
ing phase in our experiments. To simulate body temperature
and perfusion, our abattoir derived porcine bladders were
placed in a circulated organ bath. Despite this attempted
approximation of reality, vascularization of vital tissue might
result in different bladder wall temperatures in pigs.
Nonetheless, we were able to adequately assess the heating
capacity and temperature distribution of two important clin-
ical hyperthermic techniques in standardized ex-vivo condi-
tions. Moreover, TC placement in the sheep model was
restricted to intravesical, extravesical and surrounding vis-
ceral TCs [26]. Compared to our study, no information on the
intramural temperatures and depth of heat penetration was
obtained, nor was C-HT evaluated. Thus, our intramural tem-
peratures significantly add to the current understanding of
the bladder wall temperature gradient using either method.
The two different technologies used in our study in com-
bination with the bladder anatomy may explain the observed
differences in heating capacity. Ultimately, the goal of hyper-
thermia is to have a higher treatment efficacy through an
increased drug tumor tissue penetration [28]. Therefore, it
would be interesting to compare the resulting efficacy of
both RF-HT and C-HT in a clinical setting and correlate it to
the achieved tissue-drug concentrations and temperatures.
A limitation of our study is the missing bladder perfusion
that may have had an impact on the temperature gradients.
Moreover, the human situation might be different, even
though the anatomy of the pig internal urological tract,
including the bladder, closely resembles the human internal
urological tract. Nonetheless, our model fits the aim of our
study, i.e., to investigate which technique resulted in a better
energy transmission in standardized circumstances – irre-
spective of the commercial system associated with either
technique. Another methodology-derived limitation is our
small lumen catheter, which may have prevented the higher
flow required, compared to RF-HT, for C-HT by our custom-
made system. However, this catheter facilitated a flow rate
only slightly lower than that of commercially available C-HT
systems (180± 20mL/min), and provided the substantial
benefit of urethral and luminal temperature measurement.
Furthermore, we used a custom-designed, non-clinically
approved, recirculation system to heat the fluid extra-corpor-
eally with the ultimate goal of reaching a temperature of
43 C at the mucosa level. We are aware that direct extrapo-
lation to commercially available C-HT systems is not possible
due to use of a custom-made C-HT device in our model,
although we made every possible effort to control our sys-
tem similarly to commercial systems. Thus, our use of an
alternative custom-made device did not hamper our com-
parison of C-HT and RF-HT, as we were able to guarantee
stable temperatures of 43 C at the luminal mucosa level,
and a constant flow. Lastly, the exact depth of the TC loca-
tion could not be measured, but was dependent on the
surgeon’s assessment during placement.
Conclusions
Using our custom-designed device, RF-HT has a slightly
higher heating capacity for the bladder neck compared to
C-HT, resulting in an effective mild hyperthermic temperature
of the submucosa and detrusor layer. For the bladder dome,
C-HT appears to give a superior performance, suggesting
that the intravesical tumour location could be taken into
consideration if it is possible to choose a particular technique
for inducing HT. Further comparison of both heating capacity
and, most importantly, ChHT efficacy, in both preclinical and
clinical studies is warranted.
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